Improved cancer treatments aim of new biology research program

April 28, 2005

Cancer research in Alberta, Canada, is taking a major step forward with a new research program being housed at the University of Calgary. The Institute for Biocomplexity and Informatics will be led by Dr. Stuart Kauffman, a scientist known around the world for his revolutionary genetic theories, who has relocated to Alberta to work on research that could offer new ways to treat cancer.

"Attracting someone of Dr. Kauffman's calibre to Alberta speaks volumes about the quality and capability of our information and communications technology sector and of the good work being done by iCORE," said Victor Doerksen, Minister of Innovation and Science. "High quality professionals are the backbone of Alberta's innovation agenda and the key to our economic prosperity and improved quality of life."

Originally a medical doctor, Dr. Kauffman's primary work has been as a theoretical biologist studying the origin of life and molecular organization. He has added a new dimension to Darwin's theory of evolution and has founding patents in chemistry for drug discovery. Kauffman is now using powerful computing resources to test some of his theories on the systems that regulate cell growth, division and differentiation. Understanding these systems may lead to the ability to control them, which could mean new cancer treatments using cell-based approaches rather than traditional treatments such as surgery, radiation and chemotherapy.

"We plan to set up a world-class research program that will marry theory and experiment in the exploding area of systems biology," says Dr. Kauffman, the new iCORE Chair in Biocomplexity and Informatics, housed at the University of Calgary. "The opportunity here is unparalleled. We need to think big, and we have found the necessary support here. There is a wonderful collaborative environment, and the potential to mix theory and experiment is very good."

Dr. Kauffman has received an iCORE Chair and Professor Establishment grant of $850,000 per year for five years, plus a $300,000 startup grant, for a total of $4.6 million. The Institute of Biocomplexity and Informatics is being supported by the University of Calgary, in collaboration with the University of Alberta. Additional support is being sought from the Natural Sciences and Engineering Research Council of Canada, the Canada Foundation for Innovation, the provincial government, industry and philanthropists.

"Stuart Kauffman is a passionate scientist, with broad experience, enormous intellectual capacity, and a commitment to building excellent collaborative interdisciplinary teams. That passion and commitment creates the potential for highly innovative science," says Dr. Randy Goebel, President and CEO of iCORE. "Dr. Kauffman's award is a foundation for expanding a highly interdisciplinary research program that iCORE will be supporting over the coming years - bioinformatics."
-end-
iCORE was established in October 1999 by the Government of Alberta to foster world-class university-based research that supports the ICT sector. Since its inception, 20 research chairs have been established to focus on emerging areas such as wireless communications, artificial intelligence, and quantum and nanocomputing. Visit www.icore.ca for more information.

Editor's Note: See backgrounder for more information: http://icore.ca/publications/iCORE_Kauffman_News_Release.pdf

For further information contact:
Calgary Mary Anne Moser, iCORE (403) 949-3306
Greg Harris, University of Calgary (403) 220-3506 Edmonton
Keri Scobie, Alberta Innovation and Science (780) 427-0038

University of Calgary

Related Cancer Research Articles from Brightsurf:

As cancer has evolved, it is time for cancer research to do the same
Marking Lung Cancer Awareness month, a new study investigates the extent to which human-based, non-animal approaches are supplanting animal models in cancer research - comparing number of publications, funding, and publications associated with clinical trials between xenograft models and human organoids.

New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

Blueprint to beat cancer launched today by World Cancer Research Fund (WCRF)
Overweight and obesity increase cancer risk. A new report published today by World Cancer Research Fund (WCRF), and presented at the European Congress on Obesity in Vienna, shows that overweight or obesity is a cause of at least 12 cancers, five more than WCRF findings a decade ago.

Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.

UA Cancer Center research team explores anti-breast cancer properties of soy
Genistein, a major compound in soy foods, might aid in the proper functioning of a gene that can malfunction to cause breast cancer.

Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.

The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.

Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.

Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.

Read More: Cancer Research News and Cancer Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.